Arrowhead Pharmaceuticals Competitors

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

Profitability

This table compares Arrowhead Pharmaceuticals and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Arrowhead Pharmaceuticals and Alexion Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Alexion Pharmaceuticals has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

65.5% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are held by institutional investors. 4.0% of Arrowhead Pharmaceuticals shares are held by company insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Arrowhead Pharmaceuticals and Alexion Pharmaceuticals, as reported by MarketBeat.

Arrowhead Pharmaceuticals currently has a consensus target price of $82.4286, indicating a potential downside of 1.61%. Alexion Pharmaceuticals has a consensus target price of $153.1250, indicating a potential upside of 0.76%. Given Alexion Pharmaceuticals' higher possible upside, analysts plainly believe Alexion Pharmaceuticals is more favorable than Arrowhead Pharmaceuticals.

Volatility and Risk

Arrowhead Pharmaceuticals has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500.

Summary

Alexion Pharmaceuticals beats Arrowhead Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

BeiGene (NASDAQ:BGNE) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, dividends, earnings and analyst recommendations.

Earnings and Valuation

This table compares BeiGene and Arrowhead Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Arrowhead Pharmaceuticals has lower revenue, but higher earnings than BeiGene. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than BeiGene, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

60.7% of BeiGene shares are held by institutional investors. Comparatively, 65.5% of Arrowhead Pharmaceuticals shares are held by institutional investors. 9.0% of BeiGene shares are held by company insiders. Comparatively, 4.0% of Arrowhead Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

BeiGene has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for BeiGene and Arrowhead Pharmaceuticals, as reported by MarketBeat.com.

BeiGene currently has a consensus target price of $310.00, indicating a potential downside of 2.94%. Arrowhead Pharmaceuticals has a consensus target price of $82.4286, indicating a potential downside of 1.61%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Arrowhead Pharmaceuticals is more favorable than BeiGene.

Profitability

This table compares BeiGene and Arrowhead Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Arrowhead Pharmaceuticals beats BeiGene on 11 of the 14 factors compared between the two stocks.

Genmab A/S (NASDAQ:GMAB) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

Volatility and Risk

Genmab A/S has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.62, indicating that its share price is 62% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for Genmab A/S and Arrowhead Pharmaceuticals, as reported by MarketBeat.

Genmab A/S presently has a consensus target price of $42.1429, suggesting a potential upside of 20.00%. Arrowhead Pharmaceuticals has a consensus target price of $82.4286, suggesting a potential downside of 1.61%. Given Genmab A/S's higher possible upside, research analysts clearly believe Genmab A/S is more favorable than Arrowhead Pharmaceuticals.

Profitability

This table compares Genmab A/S and Arrowhead Pharmaceuticals' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Genmab A/S and Arrowhead Pharmaceuticals' revenue, earnings per share and valuation.

Genmab A/S has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

6.2% of Genmab A/S shares are owned by institutional investors. Comparatively, 65.5% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 4.0% of Arrowhead Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Genmab A/S beats Arrowhead Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Horizon Therapeutics Public (NASDAQ:HZNP) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, risk, valuation, dividends and profitability.

Profitability

This table compares Arrowhead Pharmaceuticals and Horizon Therapeutics Public's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Arrowhead Pharmaceuticals and Horizon Therapeutics Public, as reported by MarketBeat.com.

Arrowhead Pharmaceuticals presently has a consensus target price of $82.4286, suggesting a potential downside of 1.61%. Horizon Therapeutics Public has a consensus target price of $101.8889, suggesting a potential upside of 10.86%. Given Horizon Therapeutics Public's stronger consensus rating and higher probable upside, analysts plainly believe Horizon Therapeutics Public is more favorable than Arrowhead Pharmaceuticals.

Insider and Institutional Ownership

65.5% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 88.6% of Horizon Therapeutics Public shares are held by institutional investors. 4.0% of Arrowhead Pharmaceuticals shares are held by insiders. Comparatively, 4.3% of Horizon Therapeutics Public shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Arrowhead Pharmaceuticals and Horizon Therapeutics Public's gross revenue, earnings per share (EPS) and valuation.

Horizon Therapeutics Public has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Arrowhead Pharmaceuticals has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500. Comparatively, Horizon Therapeutics Public has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500.

Summary

Horizon Therapeutics Public beats Arrowhead Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

Catalent (NYSE:CTLT) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations.

Institutional & Insider Ownership

97.8% of Catalent shares are owned by institutional investors. Comparatively, 65.5% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 1.0% of Catalent shares are owned by insiders. Comparatively, 4.0% of Arrowhead Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility & Risk

Catalent has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500.

Profitability

This table compares Catalent and Arrowhead Pharmaceuticals' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Catalent and Arrowhead Pharmaceuticals' top-line revenue, earnings per share and valuation.

Catalent has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Catalent, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Catalent and Arrowhead Pharmaceuticals, as provided by MarketBeat.com.

Catalent presently has a consensus price target of $121.3750, indicating a potential upside of 4.27%. Arrowhead Pharmaceuticals has a consensus price target of $82.4286, indicating a potential downside of 1.61%. Given Catalent's stronger consensus rating and higher probable upside, analysts plainly believe Catalent is more favorable than Arrowhead Pharmaceuticals.

Summary

Catalent beats Arrowhead Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Royalty Pharma (NASDAQ:RPRX) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both finance companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, profitability, institutional ownership and dividends.

Profitability

This table compares Royalty Pharma and Arrowhead Pharmaceuticals' net margins, return on equity and return on assets.

Insider and Institutional Ownership

40.9% of Royalty Pharma shares are held by institutional investors. Comparatively, 65.5% of Arrowhead Pharmaceuticals shares are held by institutional investors. 2.5% of Royalty Pharma shares are held by insiders. Comparatively, 4.0% of Arrowhead Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Royalty Pharma and Arrowhead Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Royalty Pharma has higher earnings, but lower revenue than Arrowhead Pharmaceuticals.

Analyst Recommendations

This is a summary of recent ratings and price targets for Royalty Pharma and Arrowhead Pharmaceuticals, as provided by MarketBeat.

Royalty Pharma presently has a consensus price target of $51.8750, indicating a potential upside of 8.01%. Arrowhead Pharmaceuticals has a consensus price target of $82.4286, indicating a potential downside of 1.61%. Given Royalty Pharma's higher possible upside, equities research analysts clearly believe Royalty Pharma is more favorable than Arrowhead Pharmaceuticals.

Summary

Arrowhead Pharmaceuticals beats Royalty Pharma on 5 of the 9 factors compared between the two stocks.